Helbig I, Heinzen EL, Mefford HC, ILAE Genetics Commission. Primer Part 1-the building blocks of epilepsy genetics. Epilepsia. 2016;57(6):861–8.

Article  PubMed  Google Scholar 

Smith L, Malinowski J, Ceulemans S, Peck K, Walton N, Sheidley BR, et al. Genetic testing and counseling for the unexplained epilepsies: an evidence-based practice guideline of the National Society of Genetic Counselors. J Genet Couns. 2023;32(2):266–80.

Article  PubMed  Google Scholar 

Carvill GL, Matheny T, Hesselberth J, Demarest S. Haploinsufficiency, dominant negative, and gain-of-function mechanisms in epilepsy: matching therapeutic approach to the pathophysiology. Neurotherapeutics. 2021;18(3):1500–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samanta D, Bhatia S, Hunter SE, Rao CK, Xiong K, Karakas C, et al. Current and emerging precision therapies for developmental and epileptic encephalopathies. Pediatr Neurol. 2025;168:67–81.

Article  PubMed  Google Scholar 

Zhou L, Wang Y, Xu Y, Zhang Y, Zhu C. Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders. Mol Ther Methods Clin Dev. 2024;32(4):101357.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quilón PG, Volpedo G, Cappato S, Ferrera L, Zara F, Bocciardi R, et al. Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies. CNS Neurosci Ther. 2024;30(11):e70050.

Article  PubMed  PubMed Central  Google Scholar 

Boison D. Inhibitory RNA in epilepsy: research tools and therapeutic perspectives. Epilepsia. 2010;51(9):1659–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hildebrand MS, Dahl H-HM, Damiano JA, Smith RJH, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet. 2013;50(5):271–9.

Article  CAS  PubMed  Google Scholar 

Myers CT, Mefford HC. Advancing epilepsy genetics in the genomic era. Genome Med. 2015;7(1):91.

Article  PubMed  PubMed Central  Google Scholar 

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21.

Article  PubMed  PubMed Central  Google Scholar 

Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1349–97.

Article  PubMed  Google Scholar 

Guerrini R, Balestrini S, Wirrell EC, Walker MC. Monogenic epilepsies: disease mechanisms, clinical phenotypes, and targeted therapies. Neurology. 2021;97(17):817–31.

Article  PubMed  PubMed Central  Google Scholar 

Scheffer IE, Zuberi S, Mefford HC, Guerrini R, McTague A. Developmental and epileptic encephalopathies. Nat Rev Dis Primers. 2024;10(1):61.

Article  PubMed  Google Scholar 

Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1443–74.

Article  PubMed  Google Scholar 

Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1398–442.

Article  PubMed  Google Scholar 

Ng AC-H, Chahine M, Scantlebury MH, Appendino JP. Channelopathies in epilepsy: an overview of clinical presentations, pathogenic mechanisms, and therapeutic insights. J Neurol. 2024;271(6):3063–94.

Article  PubMed  Google Scholar 

Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia. 2010;51(9):1650–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum Mutat. 2005;25(6):535–42.

Article  CAS  PubMed  Google Scholar 

Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunklaus A, Brünger T, Feng T, Fons C, Lehikoinen A, Panagiotakaki E, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022;145(11):3816–31.

Article  PubMed  PubMed Central  Google Scholar 

Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175–92.

Article  PubMed  PubMed Central  Google Scholar 

Koh HY, Smith L, Wiltrout KN, Podury A, Chourasia N, D’Gama AM, et al. Utility of exome sequencing for diagnosis in unexplained pediatric-onset epilepsy. JAMA Netw Open. 2023;6(7):e2324380.

Article  PubMed  PubMed Central  Google Scholar 

Lai WW, Galer BS, Wong PC, Farfel G, Pringsheim M, Keane MG, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61(11):2386–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dlugos DJ, Scheffer IE, French JA, Vossler DG, Orevillo C, Polega S, et al. Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC). Epilepsia. 2026 Feb;67(2):646-659. Epub 2025 Oct 24 https://doi.org/10.1111/epi.18689

Tolete P, Knupp K, Karlovich M, DeCarlo E, Bluvstein J, Conway E, et al. Lorcaserin therapy for severe epilepsy of childhood onset: A case series. Neurology. 2018;91(18):837–9.

Article  PubMed  PubMed Central  Google Scholar 

Bialer M, Perucca E. Lorcaserin for Dravet syndrome: a potential advance over fenfluramine? CNS Drugs. 2022;36(2):113–22.

Article  CAS  PubMed  Google Scholar 

Han Z, Chen C, Christiansen A, Ji S, Lin Q, Anumonwo C, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020;12(558):eaaz6100.

Article  PubMed  Google Scholar 

Laux L, Sullivan J, Perry MS, Brunklaus A, Desurkar A, Schreiber JM, et al. Zorevunersen in children and adolescents with dravet syndrome. N Engl J Med. 2026;394(10):969–82.

Article  CAS  PubMed  Google Scholar 

Tanenhaus A, Stowe T, Young A, McLaughlin J, Aeran R, Lin IW, et al. Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet Syndrome mouse model and is well tolerated in nonhuman primates. Hum Gene Ther. 2022;33(11–12):579–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

[Internet]. [cited 2026 Mar 4]. Available from: https://aesnet.org/abstractslisting/polaris-phase-1-2-program-interim-safety-and-preliminary-efficacy-results-of-etx101-a-one-time-gene-regulation-therapy-in-young-children-with-dravet-syndrome

Matricardi S, Cestèle S, Trivisano M, Kassabian B, Leroudier N, Vittorini R, et al. Gain of function SCN1A disease-causing variants: expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication. Epilepsia. 2023;64(5):1331–47.

Article  CAS  PubMed  Google Scholar 

Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 2019;60(Suppl 3):S59-67.

PubMed